Inovio rises on Coherus collaboration for HPV-related cancer therapy development

Coherus Oncology

04/01/2024 15:22

** Shares of drug developer Invio  INO.O  rise 8.1% to 56
cents  
    ** Co announces a clinical collaboration and supply
agreement with Coherus BioSciences  CHRS.O  to test their
experimental combination therapy to treat patients with HPV-
related head and neck cancer 
    ** Under the terms of the agreement, INO is to conduct a
late-stage study testing CHRS's Loqtorzi, an already approved
treatment with its experimental immunotherapy, INO-3112 
     **  The experimental immunotherapy is designed to activate
patients' immune responses to specifically target and kill
HPV-associated tumors   
    ** Shares of CHRS were up 2.6% 
    ** INO was down 67.3% in 2023 

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))